GlassScriptPhysician profile
Sonia Badreshia
NPI 1407894074
$2,772.75
in general payments reported to CMS, 2019-2025
12 companies · $566 in 2025
The $566 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $365 · 2021: $223 · 2022: $179 · 2023: $285 · 2024: $307 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,158.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $701.98 | 2019-2025 | |
| Allergan, INC. | $696.51 | 2019-2022 | |
| Abbvie INC. | $549.44 | 2023-2025 | Botox |
| Galderma Laboratories, L.P. | $276.34 | 2019-2025 | Dysport |
| Revance Therapeutics, INC. | $203.74 | 2024-2025 | Daxxify, Daxi |
| Sun Pharmaceutical Industries INC. | $106.66 | 2024-2025 | |
| Leo Pharma INC. | $64.90 | 2024-2025 | Adbry |
| Janssen Biotech, INC. | $50.71 | 2024 | Tremfya |
| Incyte Corporation | $48.83 | 2024-2025 | Opzelura |
| Genzyme Corporation | $38.87 | 2025 | |
| Amgen INC. | $22.41 | 2025 | Otezla |
| Biofrontera INC. | $12.36 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Badreshia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.